Research and develop therapeutic candidates for cancer treatment. Focus on immuno-oncology, targeting solid tumors and advanced malignancies. Now — the numbers.
This is an established company with proven profits.
Average growth of 87% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $142.7M would still be left in the vault — a solid cushion for hard times.
The market pays 6.6× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 81% of them.
Analysts' average target sits 102% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 49% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 87% a year on average.
There is $145.6M in the vault; even if every debt were paid off, $142.7M would remain.
This stock swings about 2.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
No clear buy-side message is coming from the executive floor.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.